Efficacy of one-stage cartilage repair using allogeneic mesenchymal stromal cells and autologous chondron transplantation (IMPACT) compared to nonsurgical treatment for focal articular cartilage lesions of the knee: study protocol for a crossover randomized controlled trial

J V Korpershoek, L A Vonk, E C Kester, L B Creemers, T S de Windt, M M A Kip, D B F Saris, R J H Custers, J V Korpershoek, L A Vonk, E C Kester, L B Creemers, T S de Windt, M M A Kip, D B F Saris, R J H Custers

Abstract

Background: Articular cartilage defects in the knee have poor intrinsic healing capacity and may lead to functional disability and osteoarthritis (OA). "Instant MSC Product accompanying Autologous Chondron Transplantation" (IMPACT) combines rapidly isolated recycled autologous chondrons with allogeneic MSCs in a one-stage surgery. IMPACT was successfully executed in a first-in-man investigator-driven phase I/II clinical trial in 35 patients. The purpose of this study is to compare the efficacy of IMPACT to nonsurgical treatment for the treatment of large (2-8 cm2) articular cartilage defects in the knee.

Methods: Sixty patients will be randomized to receive nonsurgical care or IMPACT. After 9 months of nonsurgical care, patients in the control group are allowed to receive IMPACT surgery. The Knee Injury and Osteoarthritis Outcome Score (KOOS), pain (numeric rating scale, NRS), and EuroQol five dimensions five levels (EQ5D-5 L) will be used to compare outcomes at baseline and 3, 6, 9, 12, and 18 months after inclusion. Cartilage formation will be assessed at baseline, and 6 and 18 months after inclusion using MRI. An independent rheumatologist will monitor the onset of a potential inflammatory response. (Severe) adverse events will be recorded. Lastly, the difference between IMPACT and nonsurgical care in terms of societal costs will be assessed by monitoring healthcare resource use and productivity losses during the study period. A health economic model will be developed to estimate the incremental cost-effectiveness ratio of IMPACT vs. nonsurgical treatment in terms of costs per quality adjusted life year over a 5-year time horizon.

Discussion: This study is designed to evaluate the efficacy of IMPACT compared to nonsurgical care. Additionally, safety of IMPACT will be assessed in 30 to 60 patients. Lastly, this study will evaluate the cost-effectiveness of IMPACT compared to nonsurgical care.

Trial registration: NL67161.000.18 [Registry ID: CCMO] 2018#003470#27 [EU-CTR; registered on 26 March 2019] NCT04236739 [ ClinicalTrials.gov ] [registered after start of inclusion; 22 January 2020].

Keywords: Advanced therapy medicinal product (ATMP); Articular cartilage defect; Chondrocytes; Chondrons; Crossover design; Knee; Mesenchymal stromal cells (MSC); Randomized controlled trial (RCT); Surgery.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Buckwalter JA. Articular cartilage: injuries and potential for healing. J Orthop Sports Phys Ther. 1998;28:192–202. doi: 10.2519/jospt.1998.28.4.192.
    1. Gelber AC, Hochberg MC, Mead LA, Wang N, Wigley FM, Klag MJ. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133:321–328. doi: 10.7326/0003-4819-133-5-200009050-00007.
    1. Pisanu G, Cottino U, Rosso F, Blonna D, Marmotti AG, Bertolo C, et al. Large osteochondral allografts of the knee: surgical technique and indications. Joints. 2018;6:42–53. doi: 10.1055/s-0038-1636925.
    1. Brix M, Kaipel M, Kellner R, Schreiner M, Apprich S, Boszotta H, et al. Successful osteoconduction but limited cartilage tissue quality following osteochondral repair by a cell-free multilayered nano-composite scaffold at the knee. Int Orthop. 2016;40:625–632. doi: 10.1007/s00264-016-3118-2.
    1. Christensen BB, Foldager CB, Jensen J, Jensen NC, Lind M. Poor osteochondral repair by a biomimetic collagen scaffold: 1- to 3-year clinical and radiological follow-up. Knee Surg Sport Traumatol Arthrosc. 2016;24:2380–2387. doi: 10.1007/s00167-015-3538-3.
    1. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New Engl J Med. 1994;331:889–895. doi: 10.1056/NEJM199410063311401.
    1. Foldager CB, Gomoll AH, Lind M, Spector M. Cell seeding densities in autologous chondrocyte implantation techniques for cartilage repair. Cartilage. 2012;3:108–117. doi: 10.1177/1947603511435522.
    1. Grande DA, Pitman MI, Peterson L, Menche D, Klein M. The repair of experimentally produced defects in rabbit articular cartilage by autologous chondrocyte transplantation. J Orthop Res. 1989;7:208–218. doi: 10.1002/jor.1100070208.
    1. Knutsen G, Drogset JO, Engebretsen L, Grøntvedt T, Isaksen V, Ludvigsen TC, et al. A randomized trial comparing autologous chondrocyte implantation with microfracture: findings at five years. J Bone Joint Surg Am. 2007;89:2105–2112. doi: 10.2106/00004623-200710000-00002.
    1. Saris DBF, Vanlauwe J, Victor J, Almqvist KF, Verdonk R, Bellemans J, et al. Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture. Am J Sports Med. 2009;37(Suppl 1):10S–19S. doi: 10.1177/0363546509350694.
    1. Marlovits S, Hombauer M, Truppe M, Vècsei V, Schlegel W. Changes in the ratio of type-I and type-II collagen expression during monolayer culture of human chondrocytes. J Bone Joint Surg Br. 2004;86:286–295. doi: 10.1302/0301-620X.86B2.14918.
    1. Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vécsei V, et al. Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthr Cartil. 2002;10:62–70. doi: 10.1053/joca.2001.0482.
    1. de Windt TS, Sorel JC, Vonk LA, Kip MMA, Ijzerman MJ, Saris DBF. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. J Tissue Eng Regen Med. 2017;11:2950–2959. doi: 10.1002/term.2197.
    1. EMA. ChondroCelect 2020 . Accessed 15 Sep 2020.
    1. EMA. Closure of EU manufacturing site for MACI. 2014. . Accessed 3 Apr 2020.
    1. Chen WH, Lai MT, Wu ATH, Wu CC, Gelovani JG, Lin CT, et al. In vitro stage-specific chondrogenesis of mesenchymal stem cells committed to chondrocytes. Arthritis Rheum. 2009;60:450–459. doi: 10.1002/art.24265.
    1. Tsuchiya K, Chen G, Ushida T, Matsuno T, Tateishi T. The effect of coculture of chondrocytes with mesenchymal stem cells on their cartilaginous phenotype in vitro. Mater Sci Eng C. 2004;24:391–396. doi: 10.1016/j.msec.2003.12.014.
    1. Mo XT, Guo SC, Xie HQ, Deng L, Zhi W, Xiang Z, et al. Variations in the ratios of co-cultured mesenchymal stem cells and chondrocytes regulate the expression of cartilaginous and osseous phenotype in alginate constructs. Bone. 2009;45:42–51. doi: 10.1016/j.bone.2008.07.240.
    1. Bekkers JEJ, Tsuchida AI, van Rijen MHP, Vonk LA, Dhert WJA, Creemers LB, et al. Single-stage cell-based cartilage regeneration using a combination of Chondrons and Mesenchymal stromal cells. Am J Sports Med. 2013;41:2158–2166. doi: 10.1177/0363546513494181.
    1. de Windt TS, Hendriks JA, Zhao X, Vonk LA, Creemers LB, Dhert WJA, et al. Concise review: unraveling stem cell cocultures in regenerative medicine: which cell interactions steer cartilage regeneration and how? Stem Cells Transl Med. 2014;3:723–733. doi: 10.5966/sctm.2013-0207.
    1. de Windt TS, Vonk LA, Slaper-Cortenbach ICM, Nizak R, van Rijen MHP, Saris DBF. Allogeneic MSCs and recycled autologous chondrons mixed in a one-stage cartilage cell transplantion: a first-in-man trial in 35 patients. Stem Cells. 2017;35:1984–1993. doi: 10.1002/stem.2657.
    1. de Windt TS, Vonk LA, Slaper-Cortenbach ICM, van den Broek MPH, Nizak R, van Rijen MHP, et al. Allogeneic Mesenchymal stem cells stimulate cartilage regeneration and are safe for single-stage cartilage repair in humans upon mixture with recycled autologous chondrons. Stem Cells. 2017;35:256–264. doi: 10.1002/stem.2475.
    1. Roos E. KOOS FAQ. 2020.
    1. Muller KE, Edwards LJ, Simpson SL, Taylor DJ. Statistical tests with accurate size and power for balanced linear mixed models. Statist Med. 2007;26:3639–3660. doi: 10.1002/sim.2827.
    1. SAS Institute . Power and sample size for MANOVA and repeated measures with the GLMPOWER procedure. 2014.
    1. Castor EDC . Castor Electronic Data Capture. 2020.
    1. Institute for Medical Technology Assessment. Questionnaires. 2020. Accessed 13 May 2020.
    1. Dutch Healthcare Authority. 2020. . Accessed 14 Sep 2020.
    1. Zorginstituut Nederland . Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016.
    1. Seltman HJ. Experimental design and analysis. 2018. Mixed Models; pp. 357–378.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅